BioWorld Asia

Dec. 10, 2003

View Archived Issues

Actelion, Merck Enter Oral Renin Inhibitor Pact Worth Up To $272M

Swiss biopharmaceutical firm Actelion Ltd. added $10 million to its cash pile, on the strength of an exclusive alliance with Merck & Co. Inc. in the area of oral renin inhibitors. (BioWorld International) Read More

Europe Fumbles Two Major Biotech-Related Decisions

Read More

'Reverse Vaccination' Might Help Stop Unwanted Immune Response

Read More

Clinical Trials Could Become More Difficult For Small Firms

Read More

PPL On The Block; Dolly's Creator Fades Into History

Read More

Cyclacel In-Licenses Cancer Compound From Sankyo Co.

Read More

Bavarian Nordic Investing In Production Facility, R&D

Read More

Stockholm Planning Bioscience Hub; Funding Concerns Remain

Read More

French Food Safety Agency Has Bt11 Sweet Corn Doubts

Read More

Other News To Note

Read More